Navigation Links
Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018
Date:10/19/2011

s Erythematosus 35

4.2.1 Targeted Drug 35

4.2.2 Immunosuppressants 36

4.2.3 Corticosteroids 36

4.3 Key Takeaway 36

5 Systemic Lupus Erythematosus Therapeutics - Pipeline Assessment 37

5.1 Overview 37

5.2 Strategic Pipeline Assessment 37

5.3 Pipeline Analysis by Phase of Development 38

5.3.1 Systemic Lupus Erythematosus Therapeutics - Phase III Pipeline 38

5.3.2 Systemic Lupus Erythematosus Therapeutics - Phase II Pipeline 39

5.3.3 Systemic Lupus Erythematosus Therapeutics - Phase I/II Pipeline 39

5.3.4 Systemic Lupus Erythematosus Therapeutics - Phase I Pipeline 39

5.3.5 Systemic Lupus Erythematosus Therapeutics - Preclinical Pipeline 40

5.3.6 Systemic Lupus Erythematosus Therapeutics - Discovery Pipeline 40

5.4 Systemic Lupus Erythematosus Therapeutics - Pipeline by Mechanism of Action 41

5.5 Systemic Lupus Erythematosus Therapeutics - Other Promising Mechanisms of Action 42

5.6 Technology Trends Analytic Framework 43

5.7 Systemic Lupus Erythematosus Therapeutics - Promising Drugs in Clinical Development 45

5.8 Molecule Profile for Promising Drugs under Clinical Development 46

5.8.1 Atacicept 46

5.8.2 Epratuzumab 47

5.8.3 LY2127399 48

5.8.4 Orencia 49

5.9 Key Takeaway 49

6 Systemic Lupus Erythematosus Therapeutics - Clinical Trial Mapping 50

6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 50

6.2 Clinical Trials by Phase 51

6.3 Clinical Trials by Trial Status 52

6.4 Prominent Sponsors 53

6.5 Top Sponsors Participating in Systemic Lupus Erythematosus Therapeutics Clinical Trials 55

7 Systemic Lupus Erythematosus Therapeutics - Strategic Assessment 57

7.1 Key Events Impacting the Future Market 57

7.2 Future Market Competition Scenario 58

8 Systemic Lupus Erythematosus Therapeutics - Future Players 59

8.1 Introduction
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. deCODE Announces Agreement With Pfizer to Search for Variants in the Human Genome That Confer Risk of Systemic Lupus Erythematosis
2. Pevions Therapeutic Candida Vaccine Shows Robust Systemic and Mucosal Immunogenicity, While Epidemiological Survey Confirms Excellent Market Potential
3. Sangamo BioSciences Announces Data Presentation of First In Vivo Demonstration of ZFN-mediated Gene Correction Via Systemic Delivery at American Society for Hematology Meeting
4. Biologic Agents Will Drive the Systemic Lupus Erythematosus Drug Market to More Than Quadruple to Nearly $2 Billion in 2018
5. Human Genome Sciences to Host July 20 Conference Call to Discuss Top-Line Phase 3 Results for Benlysta(TM) (Formerly Lymphostat-B(R)) in Systemic Lupus Erythematosus
6. Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus
7. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
8. Anacor Achieves Milestone from GSK for Boron-Based Systemic Antibacterial Product Candidate
9. Lupus Research Institute: Benlysta(TM) Trial Results in an Historic Research Breakthrough and Victory for People With Lupus
10. Promise of a New Lupus Treatment Is a Groundbreaking Achievement
11. Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Diego, CA (PRWEB) October 22, 2014 ... balances from Sartorius, A & D Weighing, Rice ... Sartorius CPA Semi-Micro Balance . The Sartorius CPA ... for an affordable high-quality, precise, and user-friendly laboratory ... manufacturing of laboratory equipment, their laboratory balances are ...
(Date:10/22/2014)... VANCOUVER , Oct. 22, 2014 /PRNewswire/ - iCo ... ICOTF), today announced next steps for its Oral ... findings from its in vitro work ... therapy.  iCo now plans to complete pre clinical ... an initial Phase 1A clinical trial, utilizing approximately ...
(Date:10/20/2014)... 20, 2014 Mapp Biopharmaceutical,s valiant effort ... therapeutic to fight the Ebola outbreak will make ... the production of pharmaceuticals can be, according to ... that while some may be taken aback by ... with industry knowledge are well aware of the ...
(Date:10/20/2014)... , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... P. Horovitz , Ph.D., from its board of directors effective ... in August 2003, and served as its chairman from June ... on the Nominating and Corporate Governance and Audit Committees of ... more than a decade of dedicated service to GenVec, and ...
Breaking Biology Technology:Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Zola P. Horovitz To Retire From GenVec Board 2
... DIEGO, Jan . 8 Arena Pharmaceuticals, Inc. (Nasdaq: ... to present at the 27th Annual J.P. Morgan Healthcare Conference ... p.m. Eastern Time) at the Westin St. Francis Hotel in ... is scheduled to provide an overview of the company, including ...
... 8 Palomar Medical Technologies, Inc. (Nasdaq: ... of light-based systems for cosmetic treatments, today announced ... the Swedish company Q-MED AB (OMX Nordic Exchange, ... based in Uppsala, Sweden. The international distribution ...
... SAN DIEGO, Jan. 7 Volcano Corporation,(Nasdaq: ... sales of,products for the diagnosis and treatment of coronary ... its previously announced acquisition of,Axsun Technologies, Inc. , ... manufacturer of lasers and optical,engines used in medical Optical ...
Cached Biology Technology:Arena Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference 2Arena Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference 3Palomar and Q-MED AB Terminate International Distribution Agreement 2Palomar and Q-MED AB Terminate International Distribution Agreement 3Palomar and Q-MED AB Terminate International Distribution Agreement 4Palomar and Q-MED AB Terminate International Distribution Agreement 5Volcano Announces Closing of Axsun Technologies Acquisition 2
(Date:10/22/2014)... Inc. (NASDAQ: AWRE ), a leading supplier of ... third quarter ended September 30, 2014. Revenue for ... of 40% compared to $4.3 million in the same quarter ... was $4.1 million compared to $1.0 million in the third ... month period was primarily due to: i) a $1.0 million ...
(Date:10/18/2014)... genetic conditions, a certain type of exome sequencing method ... traditional molecular diagnostic methods, according to a study appearing ... to coincide with the American Society of Human Genetics ... region of the genome (the complete set of genes ... has been rapidly applied in research settings and recent ...
(Date:10/17/2014)... available in German . ... few drugs. When treating overdoses, doctors are often limited to ... if there is a combination of drugs involved. So what ... swallows his grandmother,s pills? ETH professor Jean-Christophe Leroux from the ... an answer to this question. "The task was to develop ...
Breaking Biology News(10 mins):Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Emergency aid for overdoses 2Emergency aid for overdoses 3
... better understanding of brain injury, a way to rejuvenate ... monitor their glaucoma at home, number among this years ... What surprises me every time I walk through ... involving so many NJIT graduate and undergraduate students, said ...
... French . , A new brain-imaging study by ... ghrelin - a stomach hormone, acts on specific regions of ... and eating for pleasure. This study, published in the ... understanding and treating obesity, a condition affecting millions world-wide. ...
... The potential of no-tillage (NT) soils for increasing the soil ... Most of the previous studies about SOC accrual in NT ... depth), and not for the whole soil profile. The lack ... to conclusively ascertain the effects of NT farming on SOC ...
Cached Biology News:NJIT applauds students for studies on brain injury, glaucoma and more 2Hunger hormone: Makes food more attractive 2Finding the real potential of no-till farming for sequestering carbon 2
MAb to Hu-IFN-Gamma RC2 (CD118), NON-Neutralizing, Clone MMHGR-2 Binds to but does not neutralize human interferon gamma receptor...
Recombinant Rat CINC-2 beta, CF...
SHEEP ANTI FLECAINIDE...
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
Biology Products: